Prescient Therapeutics – Meeting on The Mesa 2022
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater...
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing...
CAR-T therapy is leading the race as the holy grail to cure cancer but like...
ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement...
Prescient Therapeutics (ASX: PTX) featured in the ‘Investor Guide for Health & Biotech’ by The...
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel...
Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR...
There are many foundations and charities which aim to tackle health conditions through funding medical...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.